Covered recipient · General Payments record
FEI CAO
Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine
General Payments · PY2021–2024
$6,236.36
- Reported across 60 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $874.65 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Nalu Medical, Inc. | $357.45 | 6 |
| SPR Therapeutics, Inc | $161.91 | 4 |
| Averitas Pharma Inc. | $112.06 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $95.96 | 1 |
| Tris Pharma Inc | $80.91 | 1 |
| Medtronic, Inc. | $27.23 | 1 |
| Curonix LLC | $21.06 | 1 |
| Abbott Laboratories | $18.07 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.07 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125144507 | CMS |
| Averitas Pharma Inc. | $90.31 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133420311 | CMS |
| Averitas Pharma Inc. | $21.75 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133420315 | CMS |
| Boston Scientific Corporation | $95.96 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092572725 | CMS |
| Curonix LLC | $21.06 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132905932 | CMS |
| Medtronic, Inc. | $27.23 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119393340 | CMS |
| Nalu Medical, Inc. | $51.49 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988733 | CMS |
| Nalu Medical, Inc. | $7.74 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988729 | CMS |
| Nalu Medical, Inc. | $98.07 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988737 | CMS |
| Nalu Medical, Inc. | $24.09 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988731 | CMS |
| Nalu Medical, Inc. | $57.78 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988735 | CMS |
| Nalu Medical, Inc. | $118.28 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133988739 | CMS |
| SPR Therapeutics, Inc | $35.29 | 03/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104927704 | CMS |
| SPR Therapeutics, Inc | $15.92 | 03/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104927760 | CMS |
| SPR Therapeutics, Inc | $20.10 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104931268 | CMS |
| SPR Therapeutics, Inc | $90.60 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104939769 | CMS |
| Tris Pharma Inc | $80.91 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147231367 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.